OncoSec Medical (NASDAQ: ONCS) and TG Therapeutics (NASDAQ:TGTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Institutional & Insider Ownership
9.0% of OncoSec Medical shares are owned by institutional investors. Comparatively, 49.9% of TG Therapeutics shares are owned by institutional investors. 11.5% of OncoSec Medical shares are owned by insiders. Comparatively, 16.7% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
OncoSec Medical has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
Earnings & Valuation
This table compares OncoSec Medical and TG Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|OncoSec Medical||N/A||N/A||-$21.73 million||($1.17)||-0.85|
|TG Therapeutics||$152,381.00||4,722.90||-$104.96 million||($1.95)||-5.92|
OncoSec Medical has higher revenue, but lower earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than OncoSec Medical, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for OncoSec Medical and TG Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OncoSec Medical presently has a consensus target price of $5.33, suggesting a potential upside of 438.72%. TG Therapeutics has a consensus target price of $26.89, suggesting a potential upside of 132.80%. Given OncoSec Medical’s higher possible upside, analysts plainly believe OncoSec Medical is more favorable than TG Therapeutics.
This table compares OncoSec Medical and TG Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
OncoSec Medical beats TG Therapeutics on 7 of the 11 factors compared between the two stocks.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
About TG Therapeutics
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.